Triastek Announces Strategic Collaboration and Equity Investment to Advance the Development of Oral Medicines

Background

On October 9, 2026, Dalton Venture portfolio company Triastek (Nanjing) Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Triastek" or the "Company") announced that the Company and its wholly-owned subsidiary Triastek (Shanghai) Pharmaceutical Technology Co., Ltd. have entered into a Collaboration and License Agreement with Johnson & Johnson. The two parties will combine Johnson & Johnson's expertise in drug development with Triastek's capabilities in 3D printing pharmaceuticals and oral delivery of peptides and other drugs to jointly develop novel oral medicines. Johnson & Johnson's corporate venture capital arm, Johnson & Johnson Innovation – JJDC, Inc., is making a concurrent equity investment in Triastek.

Triastek will leverage its MED&SSE (Melt Extrusion Deposition plus Semi-Solid Extrusion) 3D printing pharmaceutical technology and 3DμS®-OM platform, combining room-temperature, low-shear manufacturing processes with tablet structure design and drug release profile engineering to address delivery challenges in oral drug development.

Senping Cheng

Dr. Senping Cheng, Founder and CEO of Triastek, said: "We are honored to enter into this strategic collaboration with Johnson & Johnson and to receive JJDC's equity investment, which fully reflects our shared vision of advancing oral drug development. We look forward to accelerating the development of next-generation innovative oral medicines through our partnership, bringing more clinically valuable treatment options to patients."

*This Collaboration and License Agreement was signed by Janssen Pharmaceutica NV as the legal entity on behalf of Johnson & Johnson.

Triastek Announces Strategic Collaboration and Equity Investment to Advance the Development of Oral Medicines

NANJING, China, October 9, 2026 — Triastek, Inc. ("Triastek" or the "Company") announced that the Company and its wholly owned subsidiary, Triastek (Shanghai) Limited, have entered into a Collaboration and License Agreement with Johnson & Johnson*. The collaboration aims to combine Johnson & Johnson's expertise in drug development with Triastek's 3D printing pharmaceutical technology and oral drug delivery capabilities for peptides and other therapeutic modalities to develop novel oral medicines. Johnson & Johnson will also make an equity investment in Triastek through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc.

Triastek will leverage its MED&SSE (Melt Extrusion Deposition plus Semi-Solid Extrusion) 3D printing pharmaceutical technology and 3D Microstructure for Oral Macromolecules (3DμS®-OM) platform, combining room-temperature, low-shear manufacturing processes with the design of tablet structures and drug release profiles to address oral delivery challenges.

Dr. Senping Cheng, Founder and CEO of Triastek, said: "We greatly value the opportunity to collaborate with Johnson & Johnson. The collaboration, together with JJDC's investment, reflects a shared commitment to advancing the development of oral medicines. We look forward to working together to accelerate the development of next-generation oral medicines and ultimately translate innovation into clinical value for patients."

*Legal entity: Janssen Pharmaceutica NV

END

ID: daltonventure

Press and hold to follow

Recommended Reading